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Human cytomegalovirus infection during pregnancy and 
detection of specific T cells by intracellular cytokine staining 
Tomoko Fujikawa, (L2) Kei Numazaki,(l) Hideomi Asanuma@) and Hiroyuki Tsutsumi(l) 
Objective: The flow cytometric assay was evaluated as a tool for real-time monitoring of human cytomegalovirus 
(HCMV)-specific cellular immunity in pregnant women. 
Methods: We screened for HCMV infection in pregnant women in Sapporo, Japan, during the year 2000, by serologic 
assays, virus isolation from urine, and PCR to detect DNA in cervical swabs. The frequencies of HCMV-specific CD4+ 
T cells in pregnant women with serum anti-HCMV IgG antibody were detected by intracellular cytokine (ICC), 
interferon-gamma (IFN-y) and tumor necrosis factor-alpha (TNF-ol) staining. 
Results: The levels of intracellular cytokines in pregnant women with serum anti-HCMV IgG antibody were significantly 
higher than those in women without anti-HCMV IgG antibody (P = 0.011 for IFN-?/ and P = 0.023 for TNF-ok) but 
lower than those in non-pregnant women with serum anti-HCMV IgG antibody. Frequencies of HCMV-specific 
CD4’ T cells were higher in infants with symptomatic congenital infection than in infants with asymptomatic 
perinatal infection. 
Conclusions: This ICC assay may reflect immunologic activity against HCMV infection in pregnant women with 
immunosuppressive conditions. 
Int J Infect Dis 2003; 7: 215-221 
INTRODUCTION 
Human cytomegalovirus (HCMV) causes fetal infection 
in 0.2-3.0% of all newborns,l and has been recognized to 
cause fetal abnormalities of microcephaly, hydrops, intra- 
cranial calcification, chorioretinitis, liver dysfunction, and 
thrombocytopenia, known as cytomegalic inclusion 
disease (CID). Approximately 90% of cases with fetal 
HCMV infection are characterized as asymptomatic at 
birth. Among symptomatic cases, 5% of newborns have 
nonspecific symptoms, and only the remaining 5% 
present with specific symptoms of CID.2 
The mortality rate of symptomatic fetal HCMV 
infection is as high as 30%, and 90-95% of survivors are 
left with neurologic sequelae. Even among those 
asymptomatic at birth, 5-17% of infants with fetal 
HCMV infection may present with neurodevelopmental 
disorders, such as sensorineural hearing loss, spastic 
diplegia or quadriplegia, and mental retardation within 
the first 4 years of life.3 Although the natural history of 
intrauterine HCMV infection is not known completely, 
a proportion of fetuses are damaged before delivery, and 
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it is sometimes difficult to obtain an accurate clinical 
diagnosis. 
Primary infection during pregnancy is more likely to 
be transmitted to the fetus (average 40%)4 with more 
severe sequelae than reactivated latent infection. How- 
ever, it was recently reported that reactivated latent 
infection was also transmitted to approximately 1% of 
fetuses, and that infants with symptomatic HCMV 
infection were born.5 Pregnant women were screened 
for HCMV infection mainly by virus isolation from 
urine, and serologic assays to detect anti-HCMV IgG 
and IgM antibodies. However, it has been pointed out 
that these conventional diagnostic assays are not always 
available for the diagnosis of primary or reactivated 
HCMV infection in pregnant women. 
The number of virus-specific T cells is recognized as 
an important factor in adaptive immunity. Recently, a 
new assay for the detection of virus-specific T ceils by 
intracellular cytokine (ICC) staining, using flow 
cytometry, was developed.6 This approach to counting 
the cells avoids the errors inherent in limiting dilution 
estimates of responder cell frequencies that result from 
apoptosis during longer-term incubation, and shows 
high sensitivity. 
In the present study, we screened for HCMV 
infection in pregnant women in Sapporo, Japan, by 
serologic assays, virus isolation from urine, and PCR 
assay to detect viral DNA in cervical swabs. HCMV- 
specific CD4+ T cells were detected in pregnant 
women with serum anti-HCMV antibodies using flow 
cytometry. 
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MATERIALS AND METHODS 
Screening of pregnant women for HCMV infection 
Materials 
Urinary specimens for virus isolation were obtained 
from 642 pregnant women visiting three obstetric clinics 
in Sapporo, Japan, during January to August 2000. 
Cervical swabs were obtained from 105 of 642 pregnant 
women for PCR assay to detect viral DNA. Another 537 
women refused to have cervical swabs taken for the 
present study. Additionally, serum samples were 
obtained for serologic assay from another 173 pregnant 
women for the confirmation of prevalence of HCMV. 
The time of sample collection was the second trimester 
of pregnancy in all women who consented to sample 
collection. 
Serologic tests 
Anti-HCMV IgG and IgM were determined using a 
commercially available enzyme-linked immunosorbent 
assay (ELISA) kit (Medac Diagnostika, Hamburg, 
Germany). (The cutoff was 0.183 for IgG and 0.181 for 
W.) 
Isolation of HCMV from urine 
HCMV from urinary specimens was isolated according 
to the standard tissue culture technique using MRC-5 
cells. The presence of HCMV was confirmed by observ- 
ation of its characteristic cytopathic effect (CPE) and by 
immunofluorescent staining with monoclonal antibodies 
against HCMV immediate early (IE) and early (E) 
antigens.7 
Detection of HCMV DNA in cervical swabs by PCR 
Cervical fluid wiped off with swabs was suspended in 
1 mL of phosphate-buffered saline (PBS) and stored 
frozen at -20°C until use. The sample was thawed and 
centrifuged at 1500 rev/min for 10 min, and DNA was 
extracted from 200 mL of the supernatant, using a 
QIAmp DNA Mini kit (QIAGEN GmbH, Hilden, 
Germany). 
According to the method of Chou and Dennison 
we amplified a part of the HCMV glycoprotein B 
(gB) gene using PCR assay. The reaction mixture in a 
volume of 50 ~J+L contained 1.5 mM MgClz, 10 mM Tris 
(pH 8.3), 12.5 U of Taq DNA polymerase (Promega, 
Madison, WI, USA), a dNTP mixture (1 mM each), 
and 0.1 mmol/L of each primer of gB1319 (5’- 
TGGAACTGGAACGTTTGGC-3’) and gB1604 (5’- 
GAAACGCGCGGCAATCGG-3’). Physiologic saline 
served as, respectively, negative control and cell lysate of 
a laboratory strain AD169 (American Type Culture 
Collection). Infected MRC-5 cells served as positive 
control. After 35 cycles of 1 min of denaturation at 95°C 
2 min of annealing at 55°C and 2 min of extension at 
72°C with GeneAmp PCR System 2400 (Perkin Elmer, 
Norwalk, CT, USA), the reaction was allowed to 
proceed for an additional 5 min at 72°C. The PCR pro- 
ducts were identified by 3% agarose gel electrophoresis. 
Detection of cytokine-positive CD4+ T cells in specific 
response to HCMV antigen 
Materials 
Fourteen samples of whole blood were obtained from 
six pregnant women with serum anti-HCMV IgG 
antibody (serum anti-HCMV IgM antibody was detected 
from one woman, HCMV was isolated from urinary 
samples from two women, and HCMV DNA was 
detected by PCR in cervical swabs from two women), 
from six normal healthy pregnant and non-pregnant 
women without serum anti-HCMV IgG antibody, and 
from two infants 2 years of age (symptomatic congenital 
and asymptomatic perinatal HCMV infections). Whole 
blood samples were also collected from four non- 
pregnant women with serum anti-HCMV IgG antibody. 
Informed consent was obtained from all women and 
parents of infants. 
Detection of HCMV-speci@ CD4’ T cells by 
intracellular cytokine staining6 
Heparinized whole blood (1 mL) was incubated with 
infected cell lysate antigen preparation for HCMV CF 
(Microbix Biosystem, Toronto, Canada), or an un- 
infected cell control (Microbix Biosystem). Staphylo- 
coccal enterotoxin B (Toxin Technology Inc., Sarasota, 
FL, USA) and PBS were used as positive and negative 
controls. Anti-CD28 antibody (Becton Dickinson, San 
Jose, CA, USA) was added to each sample (3 mg/mL) as 
a co-stimulator. 
After 2 h, brefeldin A (Sigma, Saint Louis, MI, 
USA) (10 kg/mL) was added to block the transport of 
cytokines to the cell surface. After a 6-h incubation at 
37°C EDTA at a final concentration of 2 mM was added 
for 15 min to remove adherent cells; red blood cells were 
lysed, and cells were fixed with the fluorescence- 
activated cell sorter (FACS) lysing solution (Becton 
Dickinson, San Jose, CA, USA). 
The fixed cells were washed with wash buffer, 
incubated with FACS permeabilization solution (Becton 
Dickinson) for 10 min, and stained in the dark for 
30 min with monoclonal antibodies against two 
combinations of cytokine and cell surface markers. The 
combinations were CD4-peridinin chlorophyll A 
protein (PerCP)/CD69-phycoerytherin (PE)/interferon 
(IFN)-y-fluorescein isothiocyanate (FITC), and CD4- 
PerCP/CD69-PE/tumor necrosis factor (TNF)-or-FITC. 
CD69-PE was used to detect activated T cells. 
Samples were analyzed by use of a FACS Calibur 
(Becton Dickinson) and side-scatter gating with CD4 
and CD69. Data for 10 000 gate events were analyzed by 
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use of CELL Qest (Becton Dickinson) and are shown as 
mean +. 
Statistical analysis 
For the purpose of calculation, women are classified into 
three groups according to the conditions of pregnancy 
and HCMV infection (group l-pregnant women with 
serum anti-HCMV IgG antibody; group 2-non- 
pregnant women with serum anti-HCMV IgG antibody; 
group 3-HCMV-seronegative women). We used the 
Mann-Whitney rank sum test to compare quantitative 
variables. A two-tailed P-value of 0.05 was considered 
significant. The statistical precision of test indices was 
determined by calculating the 95% confidence interval. 
RESULTS 
Screening of pregnant women for HCMV infection 
in Sapporo, 2000 (Table 1) 
Anti-HCMV IgG antibody was found in 67.6%, and 
three of 173 pregnant women (1.7%) were positive for 
anti-HCMV IgM antibody. HCMV was isolated from 
urinary samples of three of 642 pregnant women (0.5%) 
and HCMV DNA was detected by PCR in the cervical 
swabs from two pregnant women. 
Table 1. Screening of HCMV infection in pregnant wornen in 
Sapporo, Japan 
Serum anti-HCMV IgG (+) 1171173 (67.6%) 
Serum anti-HCMV IgM (+) 31173 (1.7%) 
Isolation of HCMV from urine (+) 31642 (0.5%) 
HCMV DNA from cervical swab (+) 21105 (1.9%) 
HCMV CF Control Antigen 
Anti-IFN-7 FITC 
Detection of intracellular IFN--y after HCMV 
antigen stimulation 
HCMV antigen-stimulated detection of intracellular 
IFN-y in one pregnant woman (positive for anti-HCMV 
IgG antibody and negative for urinary HCMV) is 
shown in Figure 1. After stimulation with uninfected 
control antigen, 0.01% of CD4’T cells produced IFN-7, 
while after HCMV antigen stimulation, 0.17% of CD4’ 
T cells produced INF-y. The intra-assay variation was 
less than 0.01%. 
Detection of intracellular TNF-Q! after HCMV 
antigen stimulation 
The value for TNF-ol obtained in the same sample is 
shown in Figure 2. After stimulation with uninfected 
control antigen, 0.03% of CD4+ T cells produced TNF- 
01, while after HCMV antigen stimulation, 0.26% of 
CD4+ T cells produced TNF-ar. The intra-assay variation 
was less than 0.01%. 
Frequencies of IFN-7 -positive cells after HCMV 
antigen stimulation 
The frequencies of IFN-y-positive cells in samples from 
pregnant women with anti-HCMV IgG-positive serum 
were 0.13-0.63% (0.30% + 0.23%) (Figure 3). The 
frequencies of IFN-y-positive cells in urinary HCMV- 
positive samples were 0.29% and 0.13%. Whereas the 
frequency of IFN-y-positive cells in the 2-year-old infant 
with symptomatic HCMV infection who had congenital 
hydrocephalus at birth was 0.23%, the corresponding 
value for an infant of the same age with asymptomatic 
perinatal infection was 0.01%. 
HCMV CF Antigen 
Anti-IFN-y FITC 
Figure 1. Representative fluorescence-activated cell sorter (FACS) plot of CD4+ T-cell responses to HCMV antigen by intracellular 
cytokine (ICC) staining assay. This FACS plot illustrates ICC results for HCMV-seropositive pregnant woman. Left: Negative control 
response when uninfected cell lysate is used. Right: Positive response when HCMV lysate is used. The percentage of cells positive for 
CD69 and IFN-?/ is shown for each panel. FACS analysis was done with CD4 gating. 
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Figure 2. Representative FACS plot of CD4+ T-cell responses to HCMV antigen by ICC staining assay. The percentage of ceils positive 
for CD69 and TNF-a is shown in the same sample as Figure 1. 
A sample from a pregnant woman who was negative 
for anti-HCMV IgG at 15 weeks of gestation and was 
positive for anti-HCMV IgM antibody at 25 weeks of 
gestation showed following results. The frequency of 
IFN-y-positive cells was 0.63%. The frequency of IFN- 
y-positive cells was 0.16% in one normal pregnant 
woman who had serum anti-HCMV IgG antibody and 
was negative for urinary HCMV. 
The frequencies of IFN-y-positive cells in samples 
from non-pregnant women with anti-HCMV IgG- 
positive serum were 0.04-0.63% (0.37% + 0.25%). In 
samples from pregnant women without anti-HCMV IgG 
antibody, the frequencies of IFN-y-positive cells were 
0.8 
p = 0.011 
0.6 
Figure 3. Frequencies of IFN-y-positive cells after HCMV Figure 4. Frequencies of TNF-a-positive cells after HCMV 
antigen stimulation. The samples were divided into three antigen stimulation. The samples were divided into three 
groups according to status of pregnancy and HCMV infection. groups according to status of pregnancy and HCMV infection. 
Group 1: pregnant women with serum anti-HCMV IgG Group 1: pregnant women with serum anti-HCMV IgG 
antibody. Group 2: non-pregnant women with serum anti- antibody. Group 2: non-pregnant women with serum anti- 
HCMV IgG antibody. Group 3: HCMV-seronegative women. HCMV IgG antibody. Group 3: HCMV-seronegative women. 
O.OO-0.02%. No response to HCMV antigen stimulation 
was observed. The frequencies of IFN-y-positive cells in 
samples from seropositive pregnant women were 
significantly higher than those from seronegative 
women (P = 0.011) but lower than those in samples 
from seropositive non-pregnant women. 
Frequencies of TNF-a-positive cells after HCMV 
antigen stimulation 
The frequencies of TNF-a-positive cells in pregnant 
women with serum anti-HCMV IgG antibody were 
0.04-0.34% (0.17% f 0.13%) (Figure 4).The frequencies 
p = 0.023 
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of TNF-o-positive cells in two urinary HCMV-positive 
pregnant women were 0.29% and O.O8%.The frequency 
of TNF-a-positive cells was 0.12% in an infant with 
symptomatic congenital infection, but no TNF-cx- 
positive cells were detected in an infant with asympto- 
matic perinatal infection. The frequencies of TNF-ar- 
positive cells in two cervical swab PCR-positive 
pregnant women were 0.06% and 0.04%. The frequency 
of TNF-a-positive cells in anti-HCMV IgM-positive 
pregnant woman was 0.43%. 
The frequencies of TNF-a-positive cells in samples 
from non-pregnant women with anti-HCMV IgG- 
positive serum were 0.20-0.83% (0.44% f 0.27%).As in 
the case of IFN-y, the frequencies of TNF-a-positive 
cells after antigen stimulation were O.OO-O.ll%, in 
HCMV-seronegative pregnant women. The frequencies 
of TNF-a-positive cells in samples from seropositive 
pregnant women were significantly higher than those in 
samples from seronegative women (P = 0.023), but 
lower than those in samples from seropositive non- 
pregnant women. 
DISCUSSION 
A decrease in the prevalence of serum antibodies 
against HCMV has been reported in recent years as a 
consequence of improvements in the social and 
economic conditions in Japan in the last 20 years. The 
prevalence of serum antibody to HCMV was more than 
90% among women of childbearing age in Japan,g but 
recently it has been speculated that the seroprevalence 
is decreasing.rO In 1999, Nishimura et alI1 reported that 
the prevalence of serum antibody to HCMV was 77.5% 
among all pregnant women. As antibody decreased to 
67.7% among women under 25 years of age in their 
study, young women in Japan are at greater risk for 
primary infection during pregnancy. In the present study, 
a prevalence of HCMV IgG antibody in pregnant 
women accounted for 67.6% of the study population, 
and this result is lower than our previous ones.lO The 
incidence of congenital HCMV infection may increase 
in the future. To determine strategies of intervention for 
those at risk, and to prevent sequelae, accurate prenatal 
diagnosis of congenital HCMV infection is clinically 
important. 
In practice, accurate clinical diagnosis of maternal 
primary HCMV infection is sometimes difficult, because 
most HCMV infection is asymptomatic and goes 
unnoticed. Serum anti-HCMV IgM as a parameter for 
serologic diagnosis of primary infection can be present 
in 10% of pregnant women with HCMV reactivation 
and continues to increase for about 18 months after 
onset of primary infection. HCMV can be reactivated 
more frequently in the late stage of pregnancy, because 
women often have some kind of immunosuppressive 
condition. It was reported that the urinary excretion rate 
of HCMV increased from 1% in early pregnancy to 13 % 
in late pregnancy, as determined by PCR.12 Attempts 
have been made to diagnose primary infection by the 
avidity index for serum anti-HCMV IgG antibodies or 
by a new HCMV IgM immunoblotting method,13,r4 but 
these methods do not yet provide for evaluation of 
possible prognostic markers in infected pregnant 
women and intrauterine HCMV infection.15 
Methods involving umbilical blood and amniotic 
fluid for diagnosis of intrauterine HCMV infection have 
recently been reported. l6 Excellent detection ability has 
been reported with quantitative PCR assay of amniotic 
fluid and other materials. r7 The quantitative determin- 
ation of HCMV DNA in amniotic fluid of at least lo3 
genome equivalents gave 100% certainty of detection of 
an infected fetus. Higher viral loads were associated with 
fetuses or newborns with symptomatic infections. 
Timing of amniocentesis and discretion in the inter- 
pretation of results remained as practical problems. 
About 50% of pregnant women with a suspicion of 
primary HCMV infection refused amniocentesis. 
Macrophages and natural killer (NK) cells are 
considered the main immunomodulating cells that 
control the activities of infecting cells in primary and 
latent HCMV infection, and express antiviral activity by 
producing IFN-y and TNF-ol. CD4’ and CD8’ T cells are 
also activated by HCMV infection, and produce 
interleukin 2 (IL-2) and IL-12. Asanuma et alI* 
measured serum levels of soluble IL-2 receptor (sIL-2R) 
in infants with liver dysfunction due to perinatal HCMV 
infection, and found that serum sIL-2R, one of the 
indicators of T-cell activation, was correlated with the 
severity of liver dysfunction. It is presumed that these 
cytokines are involved not only in the development of 
persistent HCMV infection and reactivation of HCMV 
infection but also in infectious transmission to the fetus. 
Numazaki et all9 found that serum levels of sIL-2R and 
IFN-7 were elevated during pregnancy in mothers who 
gave birth to babies with congenital HCMV infection. 
Based on their findings, they underlined the possibility 
of clinical application for the perinatal diagnosis of 
HCMV infection. 
Methods for the analysis of T-cell responses to 
specific virus antigen have traditionally relied on the 
limiting dilution assay and enzyme-linked immunospot 
(ELISPOT) assay. These techniques suffer from the 
drawback that they do not enable analysis of single-cell 
responses in the context of unselected cellular back- 
grounds. In addition, these methods do not allow the 
assessment of the expression of more then one cytokine 
per cell, unless T-cell clones are employed. 
Waldrop et al in 199720 described a highly sensitive 
flow cytometric technique to detect single-cell expression 
of cytokines, and to simultaneously quantify and 
phenotypically characterize virus-specific T cells. The 
sensitivity of this method for enumerating cytokine 
precursor frequencies appears to be superior to those of 
the limiting dilution assay and ELISPOT assay. Whereas 
the detection rate for active T-cell precursors in HCMV 
and mycobacteria accounts for only O.OOOl-0.001% of 
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peripheral mononuclear cells as determined using 
limiting dilution and ELISPOT assays, the flow cyto- 
metric assay detects O.OOl-0.2% of specific CD4+ cells.21 
This increased sensitivity of the flow cytometric assay is 
explained by the highly efficient capture of cytokine 
produced within the cytoplasm of the secretion-inhibited 
responding cell and the relatively short-term incubation 
period, which mitigates against the potential negative 
effect of activation-induced apoptosis. Furthermore, an 
assay using whole blood instead of peripheral blood 
mononuclear cells was reported by Suni et al in 1998.22 
It is desirable to be able to measure the in vivo effects of 
immunomodulators on cellular immunity. In the present 
study, therefore, the whole blood method of flow 
cytometric assay was employed.6J2 
The methods of screening for HCMV infection 
should be compared with the frequencies of HCMV- 
specific CD4+ T cells. A pregnant woman with serum anti- 
HCMV IgM antibody showed a higher frequency, and the 
frequency of HCMV-specific CD4’ T cells might be 
associated to some extent with virus quantity in the body. 
As pregnancy proceeds, HCMV becomes reactivated at 
the cervix.13 There was no significant difference in HCMV- 
specific CD4+T-cell numbers when virus-shedding women 
were compared to HCMV-seropositive women who were 
not excreting virus in their urine. A low frequency of 
HCMV-specific CD4+ T cells in samples of the cervical 
DNA- and urinary virus-positive specimens suggests the 
possibility of local reactivation of viruses from latent 
infection without systemic immunologic changes. 
We also evaluated specific cellular immunity in 
children with congenital HCMV infection.23 The 
frequencies of HCMV-specific CD4’T cells detected by 
ICC, both IFN-y and TNF-a, were higher in children 
with symptomatic congenital HCMV infection than in 
children with asymptomatic congenital infection. 
Categorizing findings obtained by the ICC assay may 
help to determine the prognosis of children with 
congenital HCMV. 
In summary, the flow cytometric assay for HCMV- 
specific CD4+ T cells was found to be applicable in 
pregnant women with some kind of immunosuppressive 
condition. The flow cytometric assay may be useful as a 
tool for real-time monitoring of HCMV-specific cellular 
immunity in pregnant women and have clinical 
application for the transmission of maternal immune 
activity against HCMV infection to the fetus. Further 
large numbers of patients with HCMV infection need to 
be evaluated by this assay for it to be established as a 
useful diagnostic tool. 
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